Treatment of osteoporosis with teriparatide: The Slovenian experience

The aim of this study was to investigate the characteristics of postmenopausal women prescribed with teriparatide in Slovenia, during the first decade after its approval, and the predictors of bone mineral density (BMD) improvement with treatment. We retrospectively studied postmenopausal osteoporot...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kocjan Tomaz, Sabati Rajic Antonela, Jensterle Sever Mojca, Janez Andrej, Vidmar Gaj, Orehek Nina, Marc Janja, Ostanek Barbara
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	bisphosphonates bone mineral density osteoporosis teriparatide Medicine R
Acceso en línea:	https://doaj.org/article/c7196b622419488da5cb81eed4e82add
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c7196b622419488da5cb81eed4e82add
record_format	dspace
spelling	oai:doaj.org-article:c7196b622419488da5cb81eed4e82add2021-12-05T14:10:55ZTreatment of osteoporosis with teriparatide: The Slovenian experience2391-546310.1515/med-2021-0359https://doaj.org/article/c7196b622419488da5cb81eed4e82add2021-10-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0359https://doaj.org/toc/2391-5463The aim of this study was to investigate the characteristics of postmenopausal women prescribed with teriparatide in Slovenia, during the first decade after its approval, and the predictors of bone mineral density (BMD) improvement with treatment. We retrospectively studied postmenopausal osteoporotic patients prescribed with teriparatide at tertiary center from 2006 to 2015. BMD was measured at standard sites by DXA at baseline, after 12 and 24 months. 25-hydroxyvitamin D and procollagen type I N-terminal propeptide (PINP) were measured at the same time-points. The inclusion criteria were met by 188 women (aged 71 years on average), 151 (80.3%) with postmenopausal and 37 (19.7%) with glucocorticoid-induced osteoporosis. Everyone had at least one fracture, 159 (84.6%) had ≥2 fractures, with vertebral fractures in 172 patients (91.5%). All patients had been previously on antiresorptives for 8.6 years on average. The average BMD change at lumbar spine, total hip, and femoral neck was +5.0%, −1.1%, and +0.3% after 24 months of treatment, respectively. Higher baseline PINP was associated with higher BMD increase at all sites after the first 12 months. Teriparatide was prescribed mostly to elderly women with severe osteoporosis who had sustained two or more fractures despite long-term antiresorptive therapy. Baseline PINP might predict initial BMD increase with teriparatide.Kocjan TomazSabati Rajic AntonelaJensterle Sever MojcaJanez AndrejVidmar GajOrehek NinaMarc JanjaOstanek BarbaraDe Gruyterarticlebisphosphonatesbone mineral densityosteoporosisteriparatideMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 1544-1551 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bisphosphonates bone mineral density osteoporosis teriparatide Medicine R
spellingShingle	bisphosphonates bone mineral density osteoporosis teriparatide Medicine R Kocjan Tomaz Sabati Rajic Antonela Jensterle Sever Mojca Janez Andrej Vidmar Gaj Orehek Nina Marc Janja Ostanek Barbara Treatment of osteoporosis with teriparatide: The Slovenian experience
description	The aim of this study was to investigate the characteristics of postmenopausal women prescribed with teriparatide in Slovenia, during the first decade after its approval, and the predictors of bone mineral density (BMD) improvement with treatment. We retrospectively studied postmenopausal osteoporotic patients prescribed with teriparatide at tertiary center from 2006 to 2015. BMD was measured at standard sites by DXA at baseline, after 12 and 24 months. 25-hydroxyvitamin D and procollagen type I N-terminal propeptide (PINP) were measured at the same time-points. The inclusion criteria were met by 188 women (aged 71 years on average), 151 (80.3%) with postmenopausal and 37 (19.7%) with glucocorticoid-induced osteoporosis. Everyone had at least one fracture, 159 (84.6%) had ≥2 fractures, with vertebral fractures in 172 patients (91.5%). All patients had been previously on antiresorptives for 8.6 years on average. The average BMD change at lumbar spine, total hip, and femoral neck was +5.0%, −1.1%, and +0.3% after 24 months of treatment, respectively. Higher baseline PINP was associated with higher BMD increase at all sites after the first 12 months. Teriparatide was prescribed mostly to elderly women with severe osteoporosis who had sustained two or more fractures despite long-term antiresorptive therapy. Baseline PINP might predict initial BMD increase with teriparatide.
format	article
author	Kocjan Tomaz Sabati Rajic Antonela Jensterle Sever Mojca Janez Andrej Vidmar Gaj Orehek Nina Marc Janja Ostanek Barbara
author_facet	Kocjan Tomaz Sabati Rajic Antonela Jensterle Sever Mojca Janez Andrej Vidmar Gaj Orehek Nina Marc Janja Ostanek Barbara
author_sort	Kocjan Tomaz
title	Treatment of osteoporosis with teriparatide: The Slovenian experience
title_short	Treatment of osteoporosis with teriparatide: The Slovenian experience
title_full	Treatment of osteoporosis with teriparatide: The Slovenian experience
title_fullStr	Treatment of osteoporosis with teriparatide: The Slovenian experience
title_full_unstemmed	Treatment of osteoporosis with teriparatide: The Slovenian experience
title_sort	treatment of osteoporosis with teriparatide: the slovenian experience
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/c7196b622419488da5cb81eed4e82add
work_keys_str_mv	AT kocjantomaz treatmentofosteoporosiswithteriparatidetheslovenianexperience AT sabatirajicantonela treatmentofosteoporosiswithteriparatidetheslovenianexperience AT jensterlesevermojca treatmentofosteoporosiswithteriparatidetheslovenianexperience AT janezandrej treatmentofosteoporosiswithteriparatidetheslovenianexperience AT vidmargaj treatmentofosteoporosiswithteriparatidetheslovenianexperience AT oreheknina treatmentofosteoporosiswithteriparatidetheslovenianexperience AT marcjanja treatmentofosteoporosiswithteriparatidetheslovenianexperience AT ostanekbarbara treatmentofosteoporosiswithteriparatidetheslovenianexperience
_version_	1718371627313397760

Treatment of osteoporosis with teriparatide: The Slovenian experience

Ejemplares similares